AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 02/08/24

BRIDGEWATER, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has provided a Complete Response resubmission to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral f...

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its fourth quarter and full year 2023 financial results on Friday, March 1, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eas...

2024-01-25 08:08:18 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Pre...

MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal"), granting Knigh...

- Fluorometholone Ophthalmic Suspension, USP, 0.1% - Product has 180-day competitive generic therapy exclusivity Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced the approval and launch of fluorometholone ophth...

More new product innovations in 2023, as compared to 26 in 2022 13 new products launched in the fourth quarter of 2023 Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) today announces that it has launched 39 new retail and injectable medicines in 2023, as compare...

Amneal Pharmaceuticals Inc. (AMRX) is expected to report $0.1 for Q3 2023

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 42 nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. Chirag will present on January 10 ...

2023-12-15 16:09:17 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company Amneal Pharma in pact with Strides to launch generic Vascepa Amneal Pharmaceuticals Non-GAAP EPS of $0.19 beats by $0.06, revenue of $6...

- Nasdaq move will be effective on December 27, 2023 Amneal Pharmaceuticals, Inc. (“Amneal”) (NYSE: AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market (“Nasdaq”) from the New York Stock Exchange (“NYSEȁ...